Wire · opportunities
Gene Therapy Trial for Ultra-Rare Disease Gets FDA Greenlight
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 4 September 2026 · Fusion42 review
The FDA has approved the commencement of the first US clinical trial for an experimental gene therapy targeting mucolipidosis type IV, an ultrarare pediatric neurodegenerative disease caused by MCOLN1 gene mutations.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 3 Sep 2026 and 4 Sep 2026.
◆ ◆ The Wire takeaway
Gene therapy founders focused on rare diseases now find the US market more accessible due to FDA clearance of a trial in mucolipidosis type IV. This opens a new window to fundraise and position your therapy as one of the few addressing ultrarare neurodegenerative disorders.
◆ Coverage
2 sources · first reported 3 Sep 2026 · latest 4 Sep 2026
◆ Related on Wire
◆ Topics